 NEW YORK, June 17, 2021 GLOBE NEWSWIRE -- BeyondSpring Inc. the Company or BeyondSpring NASDAQ: BYSI, a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development RD Day to discuss the development program for its novel immune agent, Plinabulin, in anti-cancer indications on Friday, June 25th, at 8:00 a.m. ET. 